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Ligandsof the tumornecrosis factor superfamily (TNFSF) (4–1BBL,
APRIL, BAFF, CD27L, CD30L, CD40L, EDA1, EDA2, FasL, GITRL,
LIGHT, lymphotoxin , lymphotoxin , OX40L, RANKL, TL1A,
TNF,TWEAK, andTRAIL) bindmembers of theTNF receptor super-
family (TNFRSF). A comprehensive survey of ligand-receptor interac-
tions was performed using a flow cytometry-based assay. All ligands
engaged between one and five receptors, whereas most receptors only
bound one to three ligands. The receptors DR6, RELT, TROY, NGFR,
and mouse TNFRH3 did not interact with any of the known TNFSF
ligands, suggesting that they either bind other types of ligands, func-
tion ina ligand-independentmanner, orbind ligands that remain tobe
identified. The study revealed that ligand-receptor pairs are either
cross-reactive between human and mouse (e.g. Tweak/Fn14, RANK/
RANKL), strictly species-specific (GITR/GITRL), or partially species-
specific (e.g.OX40/OX40L, CD40/CD40L). Interestingly, the receptor
bindingpatternsof lymphotoxinandareredundant in thehuman
butnot in themousesystem.Ligandoligomerizationalloweddetection
of weak interactions, such as that of human TNF with mouse TNFR2.
In addition,mouseAPRIL exists as two different splice variants differ-
ing by a single amino acid. Although human APRIL does not interact
with BAFF-R, the shorter variant of mouse APRIL exhibits weak but
detectable binding tomouse BAFF-R.
Although the tumor necrosis factor (TNF)5 superfamily (TNFSF)
does not exist in prokaryotes, yeast, or nematodes, it is represented by a
single member in insects and has significantly expanded in vertebrates
through gene duplication events, with 18 genes identified so far in
mouse and human (1). In Drosophila, the single TNF homologue Eiger
induces c-Jun N-terminal kinase-mediated cell death and has been
shown to modulate host response to Salmonella infection (2–4). EDA,
the closest vertebrate homologue of Eiger, is required for the develop-
ment of scales in fishes, feathers in birds, and hair, teeth, and sweat
glands in mammals (5). In birds and mammals, however, most TNFSF
and TNFRSF members are implicated in the development, mainte-
nance, and function of immune cells and secondary lymphoid organs
and participate in other functions, such as bone homeostasis (1). Several
TNFSF and TNFRSF members are being used or evaluated as drug
targets for the treatment of immune dysfunctions, cancer, and other
diseases (for reviews, see Refs. 6–10).
TNF family ligands are type II transmembrane proteinswith an extra-
cellular, homotrimeric C-terminal TNF homology domain that is fre-
quently released as a soluble cytokine upon proteolytic processing (11).
Lymphotoxin  is remarkable in that it cannot form homotrimers but
instead heterotrimerizes with lymphotoxin (12). Receptors are usually
type I and sometimes type III (BCMA, TACI, BAFF-R, and XEDAR)
membrane proteins, with the exception of OPG and DcR3, which are
secreted. Receptors are characterized by the presence of one to four
cysteine-rich domains (CRD) in their extracellular portion. Those
receptors with several CRDs adopt an elongated structure and bind at
the interface between two ligand monomers within a trimer, whereas
single CRD receptors are more compact and contact a single ligand
monomer in a trimeric ligand (13–16). Generally, one trimeric ligand
engages three monomeric receptors, a key event for the activation of
intracellular signaling pathways.
The TNF ligands have been shown to bind to one, two, or more
different receptors and vice versa. For example, RANKL promotes bone
resorption by stimulating the maturation of osteoclast precursors
through the membrane-bound receptor RANK and is regulated
through binding to the soluble decoy receptor OPG (10, 17). Experi-
mental data regarding TNFSF-TNFRSF interactions in human and
mouse and more specifically those addressing interspecies cross-reac-
tivities are scattered in the literature (if available at all) and rely on
different experimental settings or on specific reagents. In this study, we
have conducted a systematic survey of TNFSF-TNFRSF interactions
and report reactivities and cross-reactivities of human and mouse
proteins.
MATERIALS ANDMETHODS
Cell Lines and Reagents—HEK293T cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum and 5
g/ml each penicillin and streptomycin. Heparin (Liquemin 5000
IU/ml) was purchased from Roche Applied Science. The rat IgG2a
monoclonal antibody anti-TRAILR3 (LEIA) was purchased from
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Axxora (San Diego, CA), the biotinylated anti-FLAGM2 antibody from
Sigma, PE-coupled streptavidin from eBiosciences, and PE-coupled
goat anti-human IgG and PE-coupled goat anti-rat IgG (HL) from
Southern Biotech (Birmingham, AL).
Expression Constructs—An expression vector for Fc:ligands has been
described previously (18) and was used for the expression of the follow-
ing ligands (amino acid numbers are given in parentheses;  means
amino acid sequence is 100% identical to): h4–1BBL-(85–254),
m4–1BBL-(140–310), hAPRIL-H98-(98–233), mAPRIL-H98(A112)-
(98–232), mAPRIL-H98(A112)-(98–233), hBAFF-(134–285), mBAFF-
(127–309), hCD27L-(39–193), mCD27L-(52–195), hCD30L-(63–235),
mCD30L-(71–239), hCD40L-(116–61), mCD40L-(115–260), mEDA1-
(hEDA1)-(245–391), mEDA2(hEDA2)-(245–389), hFasL-(139–281),
mFasL-(106–279),hGITRL-(47–177),mGITRL-(38–173),hLIGHT-(89–
240), mLIGHT-(87–239), hLT-(43–205), mLT-(52–202), hLT-
(63–244), mLT-(63–306), hOX40L-(50–183), mOX40L-(140–310),
hRANKL(152–317), mRANKL-(157–316), hTL1A-(93–251), mTL1A-
(94–252), hTNF-(85–233), mTNF-(76–235), hTRAIL-(95–281),
mTRAIL-(120–291), hTWEAK-(141–284), mTWEAK-(94–249).
FLAG-tagged hLT-(43–205) and mLT-(52–202) were expressed
with the pFLAG vector (19) and co-transfected with the corresponding
Fc:LT to produce mouse and human LT. Although we did
not determine the ratio of LT12 and LT21 in these prepara-
tions, they probably contained a mixture of both. hTNF-(85–233),
mTNF-(76–235), mBAFF-(127–309), mAPRIL(A112)-(98–232), and
mAPRIL(A112)-(98–233) were also cloned into the pFLAG vector.
An expression vector for the extracellular domains of receptors fused
to a portion of hTRAILR3 (157–259), including the GPI addition signal,
has been described previously (20) and was used to clone the indicated
sequence of various receptors that either contained their own signal
peptide or, when indicated, were cloned after the hemagglutinin or
immunoglobulin G1 heavy chain signal peptides (HA signal and Ig sig-
nal, respectively): h4–1BB-(1–186), m4–1BB-(1–181), hBAFF-R-(2–
71) (HA signal), mBAFF-R-(2–70) (HA signal), hBCMA-(2–54) (Ig sig-
nal), mBCMA-(1–46) (Ig signal), hCD27-(1–191), mCD27-(1–182),
hCD30-(1–380), mCD30-(1–285), hCD40-(1–193), mCD40-(1–193),
hDcR3-(1–300), hDR3-(25–199) (Ig signal), mDR3-(1–194), hDR6-(1–
351), mDR6-(1–350), mDcTRAILR1-(1–158), mDcTRAILR2-(40–
171) (HA signal), hEDAR-(1–183), mEDAR-(1–183), hFas-(1–170),
mFas-(1–169), hFn14-(1–75), mFn14-(1–75), hGITR-(26–161) (HA
signal), mGITR-(1–153), hHVEM-(1–200), mHVEM-(1–206), hLTR-
(1–220), mLTR-(1–217), hNGFR-(1–250), mNGFR-(1–243), hOPG-
(1–202), mOPG-(1–214), hOX40-(1–214), mOX40-(1–209), hRANK-
(29–213) (HA signal), mRANK-(1–200), hRELT-(1–125), mRELT-(1–
165), hTACI-(2–160) (HA signal), mTACI-(2–78) (HA signal),
hTNFR1-(1–211), mTNFR1-(1–210), hTNFR2-(1–257), mTNFR2
Thr-102/Ile-108-(1–257), mTNFR2 Ser-102/Thr-108-(1–257), mTNF-
RH3-(1–162), hTRAIL-R1-(1–239), hTRAIL-R2-(1–212), mTRAIL-R-
2-(1–166), hTRAIL-R3-(1–259) (full-length), hTRAIL-R4-(1–211), hT-
ROY-(1–168), mTROY-(1–168), hXEDAR-(1–134) (Ig signal), and
mXEDAR-(2–133) (HA signal). An expression vector for Receptor:Fc
has been described previously (21) and was used for the expression of
hCD27-(1–191), mCD27-(1–182), mDcTRAILR1-(1–158), mDcTRAI-
LR2-(1–171), hFas-(1–170), mFas-(1–169), hHVEM-(1–200), mHVE-
M-(1–206), hLTR-(1–220), mLTR-(1–217), hOPG-(1–202), mOP-
G-(1–214), mTNFRH3-(1–162), hTRAIL-R1-(1–239), hTRAIL-R2-
(1–212), hTRAIL-R3-(1–240), and hTRAIL-R4-(1–211). Full-length
hFasL-(1–281), mFasL-(1–279), hTRAIL-(1–281) (FLAG), mTRAIL-
(1–291) (FLAG), hCD27L-(1–193) (FLAG),mCD27L-(1–195), hLIGH-
T-(1–240), andmLIGHT-(1–239)were cloned in the PCR3mammalian
expression vector (Invitrogen).
Transfection—For secreted proteins, 293T cells transiently trans-
fected using the calcium phosphate procedure were grown in serum-
free Opti-MEM I medium for 4–7 days. Supernatants were collected
and frozen until use. In one instance (see Fig. 2D), supernatants were
concentrated 60 before use.When concentration is indicated, protein
concentration was estimated by immunoblot using anti-FLAG or
anti-Fc antibodies with purified proteins of known concentration as
standards.
For flow cytometry stainings, 293T cells were co-transfected over-
night with expression constructs for the receptor of interest and EGFP,
washed and cultured for an additional 24 h in complete medium. For
staining and analysis, cells were detached by pipetting.
Flow Cytometry Staining—Stainings (2 105 transfected 293T
cells) were performed in round-bottomed 96-well plates for 20 min on
ice with either (a) Fc-tagged ligands followed by PE-coupled goat anti-
human IgG, (b) Fc-tagged receptor followed by PE-coupled goat anti-
human IgG, (c) 0.5 g of LEIA antibody followed by PE-coupled goat
anti-rat IgG, or (d) FLAG-tagged ligands followed by biotinylated anti-
FLAG M2 antibody and PE-coupled streptavidin. Stainings were per-
formed with 5–15 l (10–50 ng) of recombinant proteins in Opti-
MEM supernatants in a final volume of 25 l of phosphate-buffered
saline and 5% fetal calf serum.Heparin (0.1l) was added in all stainings
to prevent unspecific binding of recombinant proteins to glycosamin-
oglycans (20). The cells were analyzed on a FACScan (BD Biosciences)
using the CellQuest program.
RESULTS ANDDISCUSSION
GPI-anchored TNF Receptors Bind Cognate Recombinant Fc:Ligands
Fusion Proteins at the Cell Surface—We have developed an assay to
monitor TNFSF-TNFRSF interactions, which requires no antibodies
specific for the ligands and receptors of interest, no protein purification,
and which contains an internal negative control. In this assay, the extra-
cellular domain of each receptor is expressed as a fusion proteinwith the
C-terminal portion of TRAIL-R3 in 293T cells, togetherwith EGFP. The
C-terminal portion of TRAIL-R3 contains a repetitive amino acid
sequence and a GPI anchor that targets the receptor to the plasma
membrane (22, 23). The C-terminal portion of TRAIL-R3 is specifically
recognized by a monoclonal antibody (LEIA) that allows monitoring of
surface expression of the chimeric receptors. Fusing receptors to a gly-
colipid anchor circumvents problems that could be associated with the
use of full-length receptors, namely induction of apoptosis, intracellular
retention, or, in the case of OPG and DcR3, secretion. Finally, receptor-
expressing cells co-express EGFP, whereas untransfected, EGFP-nega-
tive cells serve as internal negative controls.
Ligands are expressed as soluble fusion proteins comprising the Fc
portion of human immunoglobulin G1 and the TNF homology domain
of TNFSF members. These fusion proteins are predicted to form hex-
amers (i.e. to contain two trimeric ligands) and to display higher avidity
for their receptors than a regular trimer (18). The Fc is detected with a
secondary PE-labeled antibody directed against human IgG1.
Cells co-transfected with EGFP, and various receptor-GPI constructs
were screened for Fc:ligands binding. Although background staining of
the various ligands varied, more than a hundred specific interactions
were readily identified based on the curved appearance of the scatter-
grams (Fig. 1). Under these experimental conditions, there were several
exceptions. Fc:mLIGHT (but not Fc:hLIGHT) failed to bind its cognate
receptors, despite the fact that the portions of hLIGHT and mLIGHT
contained in these constructs were exactly equivalent. The same was
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true for Fc:mTRAIL. In addition, Fc:hTRAIL and Fc:mFasL did not
recognize at least one of their described binding partners (Fig. 1 and data
not shown). This could result fromCys-230 oxidation inTRAIL (25, 26),
from putative detrimental effects of the Fc portion on some ligands in
the Fc:ligand fusion proteins, or could be due to the portion of the ligand
expressed. Fc:mFasL was expressed as two constructs, one containing
FIGURE 1. Ligand-receptor interactions in the TNF family. Receptors are listed on the sides and ligands at the top and bottom of the figure. Human proteins are designated h, and
mouseproteins aredesignatedm. Receptors fused to theGPI anchor of TRAIL-R3were expressed in 293T cells togetherwith anEGFP tracer (x-axis) and stainedwith ligands expressed
as Fc fusion proteins (y-axis). Receptor expression was verified by staining with the monoclonal antibody LEIA (mAb572, right column) directed against the C-terminal portion of
TRAIL-R3 that is present in all receptors. Cells were analyzed by two-color flow cytometry, and the scattergrams obtained for each receptor-ligand combination are shown. Both axes
show fluorescence intensity on a logarithmic scale (100–104). Positive interactions are boxed and are characterized by the fact that cells transfected to a high level bindmore ligand
than cells with low levels of transfection. Known interactions thatwere not detected (hTRAILwithmDcTRAILR2,mFasLwithmFas) are boxed in gray dots and contain a questionmark.
No data are shown for Fc:mLIGHT and Fc:mTRAIL, because these two ligands were not produced in an active form.,, or are shown for results obtained with full-length forms
of these two ligands (see Fig. 2). As a control, cells were transfected with the empty expression vector (Mock). Data originate from several independent experiments performedwith
an identical protocol. The entire screenwas performed once, but all negatives, where a positive interaction could have been reasonably expected (e.g. hCD40LwithmCD40), and all
positiveswere confirmed twice tomany timeswith similar results. As theportionof EDA1andEDA2used in this study is identical betweenmouseandhuman, the sets of data for EDA1
and EDA2 are shown twice. The short splice variant of mAPRIL was used in these experiments (see Fig. 4).
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the TNF homology domain only (data not shown) and the other con-
taining the entire extracellular domain (Fig. 1). Only the long formdem-
onstrated binding to hDcR3, a described receptor for hFasL (27), but
neither form interacted with mFas. We therefore expressed mFasL,
mLIGHT, mTRAIL, and hTRAIL as untagged, full-length proteins in
293T cells and detected interactions with recombinant receptor:Fc
fusion proteins. In this format, these four ligands interacted with their
cognate receptors (Fig. 2).mLIGHT interacted readilywithmLTR, but
only weak binding to mHVEM was observed (Fig. 2D).
Simple Interactions—Some interactions involve a single ligand bind-
ing to a single receptor. This is the case for the following pairs: 4–1BBL/
4–1BB, CD27L/CD27, CD30L/CD30, CD40L/CD40, EDA1/EDAR,
EDA2/XEDAR, GITRL/GITR, OX40L/OX40, and TWEAK/Fn14.
m4-1BBL and mGITRL did not recognize the corresponding human
receptors, whereas hCD40L, hGITRL, and hOX40L did not bind the
mouse receptors. In addition, h4–1BBL interacted only weakly with
m4–1BB, as seen from the convex shape of the scattergram, in which
only highly transfected cells bound the ligand (Fig. 1).
An interaction betweenTWEAK(Apo3L) andDR3 has been reported
in an earlier study (28). This interaction has not been reproduced here
or in a number of other settings (Fig. 1) (29–31) and should be consid-
ered an artifact. Instead, TWEAK interacts with Fn14, andDR3 binds to
TL1A (Fig. 1) (32, 33).
The RANKL, TRAIL Network—Expression of soluble TRAIL in 293
cells results in the oxidation of Cys-230, which is required for the che-
lation of a zinc atomat the center of the trimer, andmay explain the total
or partial lack of activity of Fc:hTRAIL and Fc:mTRAIL (25, 26). How-
ever, the membrane-bound forms of both human and mouse TRAIL
were suitable for this study of receptor binding and allowed us to repro-
duce the previously published interactions (Fig. 2A) (34).
The Immediate TNF Network—TNF, LT, LT, LIGHT, TL1A, and
FasL share at least one receptor with another ligand of the immediate
TNF family. We have confirmed the published interactions within this
subfamily (Figs. 1, 2, and 5). Curiously, in our hands, hDcR3:Fc failed to
bind efficiently to its three cognate ligands LIGHT, FasL, and TL1A
(data not shown), but the same portion of DcR3 fused to theGPI anchor
of TRAIL-R3 did show an interaction (Fig. 1). It has been shown that
DcR3 specifically loses its ability to interact with FasL (but not LIGHT)
upon proteolytic cleavage at residueArg-247, which separates theCRDs
from the C-terminal extension (35). In contrast to DcR3-Ig, GPI-an-
chored DcR3 may escape proteolytic processing or maintain a confor-
mation that allows ligand binding. We have not been able to test the
hDcR3-mLIGHT interaction.
There were marked differences in the patterns of interaction of the
lymphotoxins with their receptors in mouse and human. In the human,
both LT and LT interacted with three receptors each, whereas in
the mouse, LT bound specifically to TNFR1 and LT to LTR. This
raises the question as to whether the interactions of human LT with
HVEM or human LT with TNFR1 are physiologically relevant or
whether they represent weak interactions with no real signaling poten-
tial in vivo.
Fc:ligands allow the detection of weak interactions, because they are
predicted to contain more than one trimeric ligand (18) and to display
higher avidity for the receptors than regular trimeric soluble ligands.
This is illustrated by the unexpected observation that human TNF did
bind tomouse TNFR2 in our experimental system (Fig. 1), although it is
known that, under physiological conditions, hTNF does not bind and
cannot activate mTNFR2 (36, 37). We tested whether this result was
because of the increased avidity of Fc:hTNF or to polymorphisms in
mTNFR2. Indeed, non-obese diabetic and 129/SvJ mouse strains con-
tain the T102S and I108T polymorphisms (38, 39) (Fig. 3A) that could
potentially alter the specificity for hTNF as they correspond to amino
acids that are present in the ligand binding domain of human TNFR2
(Fig. 3A) (16). However, both polymorphic forms of mTNFR2 bound to
Fc:hTNFnearly as efficiently as the positive controls hTNFR2, hTNFR1,
andmTNFR1 but only weakly bound trimeric humanTNF (Fig. 3,B and
C). We conclude that the use of Fc:ligands, which may mimic mem-
brane-bound ligands, contributes to the sensitivity of the screen by
allowing detection of weaker interactions. However, additional experi-
ments are required to determine whether a given interaction is biolog-
ically relevant.
The BAFF and APRIL Network—The ligands BAFF and APRIL share
two receptors, TACI and BCMA. However, only BAFF can bind to
BAFF-R.We indeed confirmed these findings with hBAFF and hAPRIL
(Fig. 1). Unexpectedly,mAPRIL interactedwithmBAFF-R, although the
binding was weaker than that observed with mBAFF (Fig. 1). To our
knowledge, the binding of mAPRIL to mBAFF-R has not been reported
previously in the literature. We noticed that APRIL exists as two splice
variants differing by a single amino acid residue, Ala-112, as a result of
differential usage of alternative splice acceptor sites that are separated
by only three nucleotides (Fig. 4A). A similar case has been described for
EDA isoforms that differ by two amino acid residues (40). Both APRIL
variants were found inmouse expressed sequence tags at approximately
equal frequencies and in both “regular” APRIL and in the membrane-
bound TWE-PRIL. TWE-PRIL is the result of an intergenic splicing
event and contains the entire TNF homology domain of APRIL (41).
The APRIL splice variant lacking the Ala-112 (or Asp-112 in human)
form cannot be produced in human and was not detected in dog, pig, or
cow expressed sequence tags. The available rat expressed sequence tags
encode only the short form of APRIL. When expressed as an Fc:ligand,
both APRIL splice variants displayed equivalent binding to mTACI and
mBCMA, weaker but significant binding to mBAFF-R, and no detecta-
ble binding to hBAFF-R (Fig. 4, B and C). However, only the shorter
splice variant bound tomBAFF-R when expressed as FLAG-tagged (tri-
meric) mAPRIL (Fig. 4, B and C). This points to a specific interaction
betweenAPRIL andBAFF-R in themouse, which depends in part on the
splicing ofAPRIL. Although this interaction isweak, and despite the fact
that the phenotypes of BAFF-deficient, BAFF-R-deficient, and APRIL-
deficient mice all indicate that APRIL does not compensate for the loss
FIGURE 2. Interactions of hTRAIL, mTRAIL, mFasL, and mLIGHT with their cognate
receptors. Full-length ligandswere expressed in 293T cells togetherwith an EGFP tracer
(x-axis) and stained with receptor:Fc fusion proteins (y-axis). Both axes show fluores-
cence intensity ona logarithmic scale (100–104).A, hTRAIL,mTRAIL, andhCD27L.B, hFasL
andmFasL. C, hLIGHT, mLIGHT, and hCD27L. The question mark denotes the absence of
an expectedpositive interactionbetweenmLIGHT andmHVEM.D, same as described for
C, except that cell supernatants containing hHVEM:Fc, mHVEM:Fc, and hCD27:Fc were
concentrated 60 before use. Similar data were obtained in two or more independent
experiments.
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of BAFF with regard to BAFF-R activation (9, 42), it remains possible
that, in the mouse, APRIL or TWE-PRIL may exert some effects
through mBAFF-R. It is also possible that administration of high doses
of murine BAFF-R-Ig in the mouse might affect APRIL function in
addition to that of BAFF.
We have previously reported that mBCMA-Ig fusion protein
expressed at 100 g/ml in the sera of transgenic mice interacted quite
poorly with mBAFF and failed to inhibit the function of BAFF in vivo
(43). In contrast, the affinity of mBAFF for hBCMA-Ig is high (43) and
explains why hBCMA-Ig can block endogenousmBAFF in vivo (45, 46).
In the present study, we had no difficulty detecting the binding of
mBAFF to mBCMA-GPI and full-length mBCMA (Figs. 1 and 4 and
data not shown), suggesting that the fusion of mBCMA to an Fc but not
to a GPI anchor is detrimental for its binding to mBAFF but curiously
not for binding to mAPRIL (43). Fc:mFasL, which binds hDcR3 but not
mFas, may represent another example where the fusion to an Ig skews
the binding specificity of the ligand (Fig. 1). The lack of interaction
between mBAFF and mBCMA-Ig expressed in transgenic mice might
therefore be due, at least in part, to an indirect effect of the fusion
protein rather than to an intrinsic property of the interaction.
Orphan Receptors and Atypical Interactions—In this screen, all
TNFSF members bound to one or more receptors, but five receptors,
namely NGFR, DR6, TROY, RELT, and mTNFRH3, remained orphan.
As interactions were tested in both human and mouse, it was unlikely
FIGURE 3. hTNF does not bind polymorphic forms ofmTNFR2, unlessmultimerized as Fc:hTNF. A, alignment of a relevant portion of the second cysteine-rich domain of human
and mouse TNFR2-highlighting polymorphisms found in the C57BL/6 (BL6) and non-obese diabetic (NOD) strains of mice, respectively. B, cells were transfected with mTNFR2 or
empty plasmid (Mock), as described in the legend to Fig. 1, and stained with either Fc:TNF (hexameric) or FLAG-TNF (trimeric). Mean fluorescence intensities (vertical axis) of gated,
EGFP-positive cells are indicated. Both axes show fluorescence intensity on a logarithmic scale (100–104). C, mean fluorescence intensities (MFI) of TNF binding to TNF receptorswere
measured as described in for B and plotted as a function of ligand concentration. Comparable data were obtained in two independent experiments (more for some of the
interactions).
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FIGURE 4. Weak but significant binding of a mAPRIL splice variant to mBAFF-R. A, sequence alignment of APRIL in various species around alanine 112 (top), schematic
representation of the two splice acceptor sites in the gene ofmouseAPRIL (bottom), and location of Ala-112 in the crystal structure of themAPRIL- hTACI complex (right, based on the
ProteinData Bank atomic coordinate file 1XU1) (14). A singlemonomer is shown. B, cells transfectedwithmBAFF-R or empty plasmid (Mock), as described in the legend to Fig. 1, were
stainedwith the indicated concentrationof hexameric (Fc fusion, scattergrams) or trimeric (FLAG fusion,bottom scattergrams)mBAFF andmAPRIL splice variants.Mean fluorescence
intensities (vertical axis) of gated, EGFP-positive cells are indicated. Both axes show fluorescence intensity on a logarithmic scale (100–104). C, mean fluorescence intensities (MFI) of
mBAFF andmAPRIL binding tomBAFF-R, hBAFF-R, mTACI, andmBCMAweremeasured as described for B and plotted as a function of ligand concentration. Comparable data were
obtained in two independent experiments. sv1, splice variant 1; sv2, splice variant 2.
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that an interaction with one of the known TNF ligands would have been
missed. One possibility is that these receptors may bind heterotrimeric
ligands, similar to theLTR-LT interaction. In addition,wehave limited
our screen to ligands of the TNF family, althoughNGFR is known to inter-
act with several dimeric ligands of the neurotrophin family, such as nerve
growth factor, brain-derived neurotrophic factor, and other neurotrophins
(NT-3, NT-4/5) (47, 48). NGFR and TROY have been reported to interact
with membrane-bound partners, such as LINGO-1 and NogoR. In these
cases,myelin-derived ligandsbind theGPI-anchoredNogoR that transmits
intracellular signals through the transmembranous protein complexes
composed of NGFR, LINGO-1, and NogoR or TROY, LINGO-1, and
NogoR (49–51). There are also reports that receptors can function in the
absenceof ligand (52, 53), and someof theorphan receptorsmight function
uniquely in this manner. Finally, a number of “atypical” interactions have
been reported, for example APRIL and TACI with proteoglycans (20, 54),
HVEM with the herpes simplex virus glycoprotein D (55), CD40 with
Hsp70-peptide complexes (56), TNF with Tanaxapox virus 2L protein,
(57), LIGHT with B and T cell attenuator (58, 59), and TNF with specific
oligosaccharides (24). None of these interactions would have been uncov-
ered in the present screen.
In summary, our results, collated in Fig. 5, provide a comprehensive
survey of interactions and cross-species reactivities within the human
and mouse TNF and TNFR families.
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